Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Interest Coverage Ratio (2016 - 2023)

Historic Interest Coverage Ratio for Cartesian Therapeutics (RNAC) over the last 9 years, with Q3 2023 value amounting to 10.26.

  • Cartesian Therapeutics' Interest Coverage Ratio fell 41476.25% to 10.26 in Q3 2023 from the same period last year, while for Jun 2024 it was 38.48, marking a year-over-year decrease of 15884.13%. This contributed to the annual value of 30.5 for FY2023, which is 73595.86% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Interest Coverage Ratio of 10.26 as of Q3 2023, which was down 41476.25% from 24.78 recorded in Q2 2023.
  • In the past 5 years, Cartesian Therapeutics' Interest Coverage Ratio registered a high of 19.38 during Q2 2022, and its lowest value of 79.84 during Q2 2020.
  • For the 5-year period, Cartesian Therapeutics' Interest Coverage Ratio averaged around 19.9, with its median value being 11.08 (2020).
  • Its Interest Coverage Ratio has fluctuated over the past 5 years, first soared by 294921.72% in 2022, then crashed by 41476.25% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Interest Coverage Ratio stood at 37.52 in 2019, then skyrocketed by 70.48% to 11.08 in 2020, then surged by 151.78% to 5.74 in 2021, then tumbled by 283.55% to 10.53 in 2022, then rose by 2.51% to 10.26 in 2023.
  • Its last three reported values are 10.26 in Q3 2023, 24.78 for Q2 2023, and 22.75 during Q1 2023.